术后复发肝癌动脉化疗栓塞治疗  

Transcatheter arterial chemoembolization for postoperative recurrent hepatocellular carcinoma

作　　者：刘明放[1] 买新莲[1] 王程[1] 

机构地区：[1]宁夏医学院附属医院,宁夏银川750004

出　　处：《宁夏医学杂志》2004年第11期699-700,共2页Ningxia Medical Journal

摘　　要：目的　探讨动脉化疗栓塞治疗术后复发肝癌的疗效及影响疗效的因素。方法　 38例原发性肝癌术后患者经B超、CT及肝动脉造影检查证实为肝癌复发 ,行肝动脉化疗 (TACE) ,观察其疗效及生存情况。结果　近期有效率 (CR +PR)为 4 2 .1% ,AFP阴转为 2 9% ,下降超过 5 0 %者为 4 1%。 1、2、3年生存率分别为 76 .3%、5 2 .6 %、34.2 % ;单因素分析显示肿瘤分期早晚、病灶数目及TACE治疗次数与预后有关 (P <0 .0 5 )。结论　术后复发肝癌行TACE治疗能改善患者生存 ,足够的TACE治疗能进一步提高疗效。Objective To explore the efficacy of transcatheter arterial chemoembolization(TACE) for postoperative recurrent hepatocellular carcinoma and the factors related efficacy.Methods Transcatheter arterial chemoembolization was performed in 38 patients who were identified as having recurrent hepatocellular carcinoma by ultrasonography,computed tomography and hepatic arterial angiography after resection of hepatocellular carcinoma.The related efficacy and survival were observed.Results The response rate(CR+PR)was 42.1%;the rate of normal AFP if elevated before TACE was 29% and the rate of AFP decreased was 41%.The 1-,2-and 3-year survival rates were 76.3%,52.6% and 34.2% respectively. Univariate analysis showed that the TNM extent of lesion,the size of lesions( single or multiple) and the times of TACE were the related factors of prognosis(P<0.05).Conclusion Transcatheter arterial chemoembolization can improme the survival of patients with postoperative recurrent hepatocellular carcinoma and the enough TACE times has further improvement.

关 键 词：肝癌 复发 化疗栓塞 预后 

分 类 号：R735.7[医药卫生—肿瘤]